医学
中止
恶化
不利影响
皮肌炎
免疫系统
肌炎
免疫疗法
免疫学
易普利姆玛
癌症
抗体
肿瘤科
内科学
作者
Salman R. Punekar,Rochelle Castillo,Sabina Sandigursky,Daniel Chang Cho
标识
DOI:10.1097/cji.0000000000000380
摘要
Immune checkpoint inhibitors (ICIs) are a class of medications targeting mostly the PD-1/PD-L1 and CTLA-4 immune pathways in the treatment of many cancers. Despite the encouraging success of ICIs, they are associated with immune-related adverse events as well as exacerbation of underlying autoimmune conditions. The treatment of these conditions often involves discontinuation of ICI in addition to the utilization of immunomodulatory agents. In this report, we discuss a case in which a patient with metastatic renal cell carcinoma experienced exacerbation of underlying paraneoplastic dermatomyositis after treatment with ICI. He was successfully continued on ICI with the use of intravenous immunoglobulin. The patient experienced adequate control of his myositis but also experienced deepening of his antitumor response.
科研通智能强力驱动
Strongly Powered by AbleSci AI